Rigel Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACTS (Details)

SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACTS (Details)	1 Months Ended									6 Months Ended	12 Months Ended
	Nov. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Jan. 31, 2024 USD ($)	May 31, 2022 USD ($)	Apr. 30, 2022 USD ($)	Apr. 30, 2021 USD ($)	Feb. 29, 2020 USD ($)	Jan. 31, 2019 USD ($)	Oct. 31, 2018 USD ($)	Apr. 01, 2024 USD ($)	Dec. 31, 2025 USD ($) period	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2021 USD ($)	Jan. 31, 2025 USD ($)	Dec. 31, 2022 USD ($)	Oct. 31, 2019 USD ($)
Collaborations
Upfront payment						$ 125,000,000.0
Right to opt out of agreement, different specified times \| period											2
Payment of cost share to collaboration partner											$ 0	$ 3,605,000	$ 2,632,000
Release of cost share liability											39,981,000	0	0
Cost of product sales											19,621,000	18,647,000	7,110,000
Accounts receivable											51,763,000	41,615,000
Revenue from contract with customer, excluding assessed tax											294,282,000	179,278,000	116,882,000
Deferred revenue											$ 1,355,000	1,355,000
Maximum
Collaborations
Collaborative arrangement potential payment percent		30.00%
Minimum
Collaborations
Collaborative arrangement potential payment percent		20.00%
ocadusertib
Collaborations
Company's percentage of development costs											20.00%
Financing component liability											$ 57,900,000
Financing liability interest accretion discount rate (in percent)											6.40%
Revenue, remaining performance obligation																$ 67,100,000
Contract with customer, liability											$ 0	0
ocadusertib \| Maximum
Collaborations
Funding commitment										$ 65,000,000.0	65,000,000.0
Non-CNS penetrant IP
Collaborations
Revenue recognized														$ 60,400,000
fostamatinib
Collaborations
Government contracts revenue											$ 300,000	0	1,100,000
Government Assistance, Operating Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]											Revenue from contract with customer, excluding assessed tax
Rezlidhia
Collaborations
Company's percentage of development costs		50.00%
Grifols
Collaborations
Upfront payment								$ 30,000,000.0
Contract with customer, liability											$ 0	0
Grifols \| fostamatinib
Collaborations
Collaborative payment received							$ 20,000,000.0
Grifols \| fostamatinib \| Maximum
Collaborations
Royalty payment as a percentage of net sales								30.00%
Grifols \| Royalty
Collaborations
Revenue recognized											7,200,000	5,100,000	3,200,000
Kissei
Collaborations
Contingent payments due to collaborative agreements									$ 115,000,000.0
Upfront payment									$ 33,000,000.0
Collaborative arrangement payment percent									20.00%
Revenue from contract with customer, excluding assessed tax											4,200,000	10,400,000	2,200,000
Kissei \| fostamatinib
Collaborations
Contract with customer, liability											1,400,000	1,400,000			$ 3,000,000.0
Collaborative payment received					$ 5,000,000.0
Accounts receivable																20,000,000.0
Kissei \| Rezlidhia
Collaborations
Upfront payment		$ 10,000,000.0
Revenue recognized		10,000,000.0
Potential payments		152,500,000
Company's share of development costs, limit		$ 3,000,000.0
Forma \| Sublicense revenue fee
Collaborations
Cost of product sales												2,300,000
Medison
Collaborations
Contract with customer, liability											0	0
Medison \| fostamatinib
Collaborations
Revenue recognized											1,100,000	500,000	500,000
Medison \| fostamatinib \| Product Financing Arrangement
Collaborations
Contract with customer, liability																	$ 5,000,000.0
Knight
Collaborations
Revenue recognized											0	0	0
Deferred revenue											0	0
Dr. Reddy's
Collaborations
Upfront payment	$ 4,000,000.0
Revenue recognized											100,000
Potential payments	$ 36,000,000.0
Collaborative arrangement payment percent	30.00%
Dr. Reddy's \| fostamatinib
Collaborations
Upfront payment												4,000,000.0
Dr. Reddy's \| Sublicense revenue fee
Collaborations
Cost of product sales												900,000
Development and regulatory milestones by non-CNS disease products
Collaborations
Contingent payments due to collaborative agreements											330,000,000.0
Product-by-product Sales Milestone
Collaborations
Contingent payments due to collaborative agreements											100,000,000.0
Development and regulatory milestones by CNS disease products
Collaborations
Contingent payments due to collaborative agreements											256,000,000.0
Central Nervous System, Product-by-product Sales Milestone
Collaborations
Contingent payments due to collaborative agreements											150,000,000.0
Licensed Rights \| Non-CNS penetrant IP
Collaborations
Revenue, remaining performance obligation																$ 6,700,000
Commercial Milestones \| Grifols
Collaborations
Contingent payments due to collaborative agreements								$ 297,500,000
Upon EMA approval of fostamatinib for treatment of chronic ITP \| Grifols \| fostamatinib
Collaborations
Collaborative payment received							17,500,000
Creditable advance royalty payment \| Grifols \| fostamatinib
Collaborations
Collaborative payment received							$ 2,500,000
Delivery of drug supply for commercialization \| Grifols
Collaborations
Revenue recognized											6,100,000	4,000,000.0	5,600,000
Collaborative Arrangement
Collaborations
Contingent payments due to collaborative agreements											1,100,000,000
Collaborative Arrangement \| Specified Development Events
Collaborations
Contingent payments due to collaborative agreements											179,500,000
Collaborative Arrangement \| Specified Regulatory Events
Collaborations
Contingent payments due to collaborative agreements											270,600,000
Collaborative Arrangement \| Specified Product Launch Events
Collaborations
Contingent payments due to collaborative agreements											$ 637,000,000.0
Amended Lilly Agreement \| ocadusertib
Collaborations
Funding commitment												$ 40,000,000.0
Agreement opt-out right, exercise period											30 days
Payment of cost share to collaboration partner										$ 21,400,000
Commercial and license agreements \| Knight
Collaborations
Upfront payment				$ 2,000,000.0
Commercial and license agreements \| Knight \| Maximum
Collaborations
Contingent payments due to collaborative agreements				$ 20,000,000.0
Collaborative arrangement payment percent				30.00%
Commercial and license agreements \| Knight \| Minimum
Collaborations
Collaborative arrangement payment percent				20.00%
Strategic collaboration agreement with MD Anderson \| Rezlidhia
Collaborations
Payment of cost share to collaboration partner											$ 5,300,000
Amount due to collaboration partner													$ 15,000,000.0
Collaboration period											5 years
Strategic collaboration agreement with CONNECT \| Rezlidhia
Collaborations
Amount due to collaboration partner			$ 3,000,000.0
Collaboration period			4 years

- Details

Name:	srt_CounterpartyNameAxis=rigl_FormaTherapeuticsHoldingsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: